Mirati Therapeutics, Inc., a clinical-stage oncology company, develops targeted therapeutics to address the genetic, epigenetic, and immunological promoters of cancer. The company is involved in developing sitravatinib, an oral spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of solid tumor; and in Phase Ib clinical trial to treat non-small cell lung cancer (NCSLC) patients with CBL, chromosome 4q12, and RET genetic alterations, as well as mocetinostat, an orally administered spectrum-selective Class 1 histone deacetylase inhibitor that is in Phase II clinical trial in combination with durvalumab for the treatment of patients with NSCLC. Its preclinical development stage product candidate include KRAS G12C inhibitor program to address mutations and tumors. The company has a collaboration and license agreement with BeiGene, Ltd. to develop manufacture and commercialize sitravatinib. It also has collaboration with Astex Pharmaceuticals, Inc. and Merck & Co., Inc.; Array BioPharma, Inc.; and Bristol-Myers Squibb Company to develop and commercialize products. Mirati Therapeutics, Inc. is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone858-332-3410
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees51
OptionableOptionable
Mirati Therapeutics (NASDAQ:MRTX) Frequently Asked Questions
What is Mirati Therapeutics' stock symbol?
Mirati Therapeutics trades on the NASDAQ under the ticker symbol "MRTX."
How were Mirati Therapeutics' earnings last quarter?
Mirati Therapeutics Inc (NASDAQ:MRTX) posted its quarterly earnings results on Tuesday, November, 6th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.87) by $0.02. View Mirati Therapeutics' Earnings History.
When is Mirati Therapeutics' next earnings date?
What price target have analysts set for MRTX?
10 equities research analysts have issued twelve-month price objectives for Mirati Therapeutics' shares. Their predictions range from $37.00 to $85.00. On average, they anticipate Mirati Therapeutics' share price to reach $60.00 in the next twelve months. This suggests that the stock has a possible downside of 17.4%. View Analyst Price Targets for Mirati Therapeutics.
What is the consensus analysts' recommendation for Mirati Therapeutics?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mirati Therapeutics in the last year. There are currently 1 hold rating and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mirati Therapeutics.
What are Wall Street analysts saying about Mirati Therapeutics stock?
Here are some recent quotes from research analysts about Mirati Therapeutics stock:
- 1. According to Zacks Investment Research, "Mirati Therapeutics, Inc. is a biopharmaceutical company. It engaged in the development of novel therapeutics for the treatment of cancer. Mirati Therapeutics, Inc., formerly known as MethylGene Inc., is based in Montreal, Canada. " (1/15/2019)
- 2. HC Wainwright analysts commented, "We derive our $65 price target from a sum-of-the-parts analysis based on probability-adjusted revenue forecasts for sitravatinib and mocetinostat. We use the net present value of our revenue forecast through 2027, apply a 50% probability of success (POS) for sitravatinib in combination with checkpoint inhibitors, a 45% POS for sitravatinib monotherapy, 15% POS for mocetinostat, our YE2018 fully diluted net cash estimate of $4.79/share, and we value the early stage pipeline at $5.38/ share to arrive at our price target. We assume a 20% discount rate for the NPV of the pipeline and a P/S multiple of 4x." (11/12/2018)
Has Mirati Therapeutics been receiving favorable news coverage?
Press coverage about MRTX stock has been trending neutral this week, InfoTrie Sentiment reports. The research firm identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Mirati Therapeutics earned a news sentiment score of 0.2 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the near future.
Who are some of Mirati Therapeutics' key competitors?
Some companies that are related to Mirati Therapeutics include Genmab A/S (GNMSF), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS), Beigene (BGNE), Jazz Pharmaceuticals (JAZZ), SAGE Therapeutics (SAGE), Nektar Therapeutics (NKTR), Loxo Oncology (LOXO), Marina Biotech (MRNA), Perrigo (PRGO), Catalent (CTLT), Dr.Reddy's Laboratories (RDY) and Amarin (AMRN).
Who are Mirati Therapeutics' key executives?
Mirati Therapeutics' management team includes the folowing people:
- Dr. Rodney W. Lappe, Exec. Chairman (Age 64)
- Dr. Charles M. Baum, Pres, CEO & Director (Age 61)
- Dr. James Christensen, Chief Scientific Officer (Age 51)
- Dr. Isan Chen, Exec. VP and Chief Medical & Devel. Officer (Age 57)
- Mr. Jamie A. Donadio, Sr. VP & CFO (Age 44)
Who are Mirati Therapeutics' major shareholders?
Mirati Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.97%), Jennison Associates LLC (3.54%), Geode Capital Management LLC (0.91%), Northern Trust Corp (0.80%), Amundi Pioneer Asset Management Inc. (0.78%) and Lord Abbett & CO. LLC (0.78%). Company insiders that own Mirati Therapeutics stock include Aaron I Davis, Boxer Capital, Llc, Charles M Baum, Craig A Johnson, Jamie A Donadio, Jamie Christensen, Tuesday Thirteen Inc and Venbio Select Advisor Llc. View Institutional Ownership Trends for Mirati Therapeutics.
Which institutional investors are selling Mirati Therapeutics stock?
MRTX stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC, Broadfin Capital LLC, Dimensional Fund Advisors LP, Bank of New York Mellon Corp, MetLife Investment Advisors LLC, Virtus ETF Advisers LLC, New York State Common Retirement Fund and Bellevue Group AG. Company insiders that have sold Mirati Therapeutics company stock in the last year include Aaron I Davis, Boxer Capital, Llc, Charles M Baum, Craig A Johnson, Jamie A Donadio and Jamie Christensen. View Insider Buying and Selling for Mirati Therapeutics.
Which institutional investors are buying Mirati Therapeutics stock?
MRTX stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Jennison Associates LLC, Perceptive Advisors LLC, Rhenman & Partners Asset Management AB, Amundi Pioneer Asset Management Inc., RTW Investments LP, Squarepoint Ops LLC and Geode Capital Management LLC. Company insiders that have bought Mirati Therapeutics stock in the last two years include Boxer Capital, Llc and Venbio Select Advisor Llc. View Insider Buying and Selling for Mirati Therapeutics.
How do I buy shares of Mirati Therapeutics?
Shares of MRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Mirati Therapeutics' stock price today?
One share of MRTX stock can currently be purchased for approximately $72.62.
How big of a company is Mirati Therapeutics?
Mirati Therapeutics has a market capitalization of $2.50 billion. The biotechnology company earns $-70,420,000.00 in net income (profit) each year or ($2.78) on an earnings per share basis. Mirati Therapeutics employs 51 workers across the globe.
What is Mirati Therapeutics' official website?
How can I contact Mirati Therapeutics?
Mirati Therapeutics' mailing address is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-332-3410 or via email at [email protected]
MarketBeat Community Rating for Mirati Therapeutics (NASDAQ MRTX)
MarketBeat's community ratings are surveys of what our community members think about Mirati Therapeutics and other stocks. Vote "Outperform" if you believe MRTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
